Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines

被引:193
作者
Barosi, G [1 ]
机构
[1] Policlin San Matteo, Ist Ricovero & Cura Carrattere Sci, Lab Informat Med, I-27100 Pavia, Italy
关键词
D O I
10.1200/JCO.1999.17.9.2954
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Myelofibrosis with myeloid metaplasia (MMM) is a chronic myeloproliferative disorder characterized by bane marrow fibrosis and extramedullary hematopoiesis, Recent studies provide definite diagnostic criteria and prognostic classifications of the disease, and allogeneic stem-cell transplantation (5CT) now offers a chance of curing the disease. In order to put diagnostic criteria and prognostic classifications of the disease into the perspective of developing guidelines for treatment strategies, all studies published in the English literature over the last 30 years were reviewed. Materials and Methods: Studies were identified through a MEDLINE search (1966 to present) and from the bibliographies of relevant articles. Results: The Italian Consensus Conference on diagnostic criteria is a structured enterprise aimed at formulating a definition of MMM that will be used for enrolling patients onto clinical studies, It relies on the obligatory presence of myelofibrosis and on the exclusion of the BCR-ABL rearrangement or Philadelphia chromosome, in association with combinations of traditional features. Prognostic scores allow us to identify classes of patients on the basis of hemoglobin, age, WBC count, and chromosomal abnormalities. Several nonrandomized studies have indicated that allogeneic SCT for patients under the age of 55 is effective in prolonging survival in more than 50% of cases and in possibly curing the disease. Patients with the most severe prognosis are candidates. Conclusion: "Consensus" methodology offers a definition of MMM useful for conducting and reporting clinical studies. A detailed knowledge of prognostic factors can help to delineate guidelines for addressing patients with allogeneic SCT. (C) 1999 by American Society of Clinical Oncology.
引用
收藏
页码:2954 / 2970
页数:17
相关论文
共 203 条
[1]   Major effects of TPO delivered by a single injection of a recombinant adenovirus on prevention of septicemia and anemia associated with myelosuppression in mice: risk of sustained expression inducing myelofibrosis due to immunosuppression [J].
Abina, MA ;
Tulliez, M ;
Lacout, C ;
Debili, N ;
Villeval, JL ;
Pflumio, F ;
Wendling, F ;
Vainchenker, W ;
Haddada, H .
GENE THERAPY, 1998, 5 (04) :497-506
[2]  
Anderson J. E., 1995, Blood, V86, p388A
[3]  
Andreasson B, 1997, EUR J HAEMATOL, V59, P171
[4]   Interstitial deletion constitutes the major mechanism for loss of heterozygosity on chromosome 20q in polycythemia vera [J].
Asimakopoulos, FA ;
Gilbert, JGR ;
Aldred, MA ;
Pearson, TC ;
Green, AR .
BLOOD, 1996, 88 (07) :2690-2698
[5]  
BANDINI G, 1994, BONE MARROW TRANSPL, V3, P105
[6]   The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia [J].
Barosi, G ;
Ambrosetti, A ;
Finelli, C ;
Grossi, A ;
Leoni, P ;
Liberato, NL ;
Petti, MC ;
Pogliani, E ;
Ricetti, M ;
Rupoli, S ;
Visani, G ;
Tura, S .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (04) :730-737
[7]  
BAROSI G, 1983, CANCER, V52, P1290, DOI 10.1002/1097-0142(19831001)52:7<1290::AID-CNCR2820520726>3.0.CO
[8]  
2-8
[9]   A PROGNOSTIC CLASSIFICATION OF MYELOFIBROSIS WITH MYELOID METAPLASIA [J].
BAROSI, G ;
BERZUINI, C ;
LIBERATO, LN ;
COSTA, A ;
POLINO, G ;
ASCARI, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (04) :397-401
[10]  
Barosi G, 1990, Haematologica, V75 Suppl 4, P48